OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.
Catalent announced on August 9, 2022 that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty contract development and manufacturing organization (CDMO), for $475 million from Mayne Pharma Group Limited.
Catalent will strengthen its capabilities in integrated oral solid formulation development, manufacturing, and packaging, as well as expand its capacity to handle highly potent compounds upon the completion of the acquisition.
The acquisition will also include Metrics’ 333,000-square-foot facility located in Greenville, NC. The facility features comprehensive capabilities to accelerate and de-risk customer programs from early development through commercial launch through a streamlines one-site solution.
“This acquisition will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent’s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs. This capacity is particularly important for customers with R&D pipelines featuring accelerated, orphan, and rare disease programs for oncology and other important therapeutic areas,” said Dr. Aris Gennadios, group president of Catalent’s Pharma & Consumer Health segment, in a press release.
“Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid CDMO. Catalent, a global leader in advanced drug development and manufacturing, is well-positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers,” said Scott Richards, CEO of Mayne Pharma.